Sat.Jun 10, 2023 - Fri.Jun 16, 2023

article thumbnail

The ingredients of a successful biopharma collaboration

PharmaVoice

Collaboration is important along the entire spectrum and lifecycle of biopharma, and finding an effective partner is harder than it sounds.

Biopharma 105
article thumbnail

Discover If Your Medical Sales Reps Feel Safe Opening Up to You

MedReps

Communication is important, especially between medical sales reps and sales team leaders. In order for everyone to be on the same page, as well as deal with successes and setbacks accurately, there needs to be open communication. If your medical sales reps are too afraid to talk to you about their issues with the job, such as problems making a certain sale or the inability to find a certain client’s pain point, then they will more than likely not meet their quotas and start looking to find anoth

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How steep is pharma’s patent cliff?

PharmaVoice

The big pharma patent cliff is almost here — and could change the face of the industry. Here’s a look at the key stats behind the coming wave of blockbuster losses.

Pharma 52
article thumbnail

BioNTech to defend itself against COVID-19 vaccine injury claim in Germany

Fierce Pharma

Two years after the initial COVID-19 vaccine push swept across the globe, Pfizer’s COVID-19 vaccine partner BioNTech is heading to court in its home country of Germany to defend itself against alle | The drugmaker will defend itself against claims from a German healthcare worker who sued the company for at least 150,000 euros ($161,500). The plaintiff alleges she suffered bodily harm resulting from Pfizer and BioNTech's Comirnaty vaccine.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

On 9 May, National Fentanyl Awareness Day was observed in recognition of the US opioid crisis. Accordingly, the development of non-opioid painkillers is experiencing a surge in activity and despite numerous novel targets receiving high levels of attention, cannabinoids have emerged as strong favourites to replace opioid-related medications. The North American opioid epidemic highlights limitations in opioid use, such as the potential for drug abuse and overdose.

Medical 143
article thumbnail

Which Digital Health Tools Will Be the Greatest Victim to Turnover from Hospitals?

MedCity News

Hospitals’ digital health adoption exploded during the pandemic, leading to many vendor contracts spanning three to five years. As these contracts reach their expiration dates over this year and next, a new report predicts that telemedicine platforms and remote patient monitoring tools face the highest risk of being turned over by hospitals.

Leads 129

More Trending

article thumbnail

Bayer needs 'midsize acquisition' to reach $10B oncology sales goal, exec says

Fierce Pharma

Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.

article thumbnail

Cardiff University begins study of schizophrenia therapy

PharmaTimes

The treatment candidate, known as MDI-26478, is a positive allosteric modulator of the AMPA receptor - News - PharmaTimes

101
101
article thumbnail

Digital Health’s ROI Reckoning: How To Uncover New Value From Old Investments

MedCity News

To increase your return on technology investment, start with an audit of existing technology. Where is it falling short? Do problems stem from lack of functionality or troubles with adoption? What do all users think?

126
126
article thumbnail

World’s largest lutetium-177 production site opens

European Pharmaceutical Review

A new therapeutic radionuclide facility, the world’s largest production site of lutetium-177, has opened in Germany. ITM Isotope Technologies Munich SE ( ITM )’s manufacturing plant in Neufahrn near Munich will produce the innovative medical isotope for targeted cancer therapies. “Radiopharmaceuticals are an essential new class of anti-cancer drugs that have the potential to improve therapy outcomes and quality of life for many patients.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Merck's Keytruda aims for updated stomach cancer label with positive data

Fierce Pharma

Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. | After scoring accelerated approval to treat HER2-positive stomach cancer in 2021, the drug has now shown it can stave off tumor progression in patients with PD-L1 positive tumors.

Patients 345
article thumbnail

Boost Local Visibility: Top Local SEO Tips for Multilocation Healthcare Businesses

Healthcare Success

Consumers across the globe have come to rely on search engines for reliable, trustworthy, accurate, and timely healthcare information. This has significantly increased competition among providers, making SEO—particularly local SEO—a crucial part of any digital marketing strategy. Local SEO is beneficial for any size business but critical for multilocation companies.

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

The consensus is 2022 was a challenging year for digital health companies. Venture capital and other startup investment in the U.S. digital health sector plummeted to $15 billion from more than $29 billion in 2021, according to Rock Health. Market analysts CB Insights similarly tracked private investment last year in U.S. digital health at $17.7 billion in 2022 — down 56% from $40.2 billion in 2021.

Pharma 123
article thumbnail

FDA approves new cell therapy manufacturing plant

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved commercial production at Bristol Myers Squibb’s newest cell therapy manufacturing facility in Devens, Massachusetts. The 244,000 square foot facility in Devens is BMS’ third commercial cell therapy facility in the US. It is located on the company’s existing Devens site, which has been developing, producing, and testing clinical and commercial medicines for over a decade.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report

Fierce Pharma

In the battle for superiority in the field of next-gen diabetes and obesity treatments, Novo Nordisk holds the lead as the developer of the metabolism-regulating treatment semaglutide. | In the battle for diabetes and obesity superiority, Novo Nordisk holds a head start as the original developer of the metabolism-regulating treatment semaglutide. But Eli Lilly is quickly gaining ground and is primed to become the market leader with its GLP-1 treatment Mounjaro, according to GlobalData.

Leads 340
article thumbnail

Invizius’ ‘angry blood’ research recruits 300th patient

PharmaTimes

525-patient trial intends to assess ‘complement activation’ during HD in patients with end stage renal failure - News - PharmaTimes

article thumbnail

CMS Tests New Primary Care Model in 8 States

MedCity News

The Making Care Primary Model will be tested by the Center for Medicare and Medicaid Innovation from July 1, 2024, to December 31, 2034, in Colorado, Massachusetts, Minnesota, New Jersey, New Mexico, New York, North Carolina and Washington.

121
121
article thumbnail

Chikungunya vaccine demonstrates 99 percent immune response

European Pharmaceutical Review

If approved, VLA1553 could become the first licensed chikungunya vaccine” A single vaccination of VLA1553 has been shown to produce neutralising antibody levels, thought to protect against chikungunya disease in 99 percent of Phase III trial participants. The chikungunya vaccine candidate is the only one globally for which regulatory review processes are underway.

Safety 105
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Game on, AbbVie. Roche's Columvi nabs FDA nod as 2nd bispecific for large B-cell lymphoma

Fierce Pharma

Less than a month after AbbVie and Genmab won FDA approval for Epkinly, Roche has crossed the finish line with its bispecific answer to large B-cell lymphoma. | Less than a month after AbbVie and Genmab won FDA approval for Epkinly, Roche has crossed the finish line with its bispecific answer to large B-cell lymphoma, though with a narrower label.

FDA 328
article thumbnail

Recent Trends Impacting Funding and Access to Rare Disease Therapies

PM360

Funding and access are not new topics of conversation in the rare disease space. Genzyme made headlines in the ’90s when it launched the enzyme replacement therapy Cerezyme for a then-unprecedented $300,000 per year. In 2007, Alexion set a new pricing milestone of $500,000 annually for Soliris , a treatment for an ultra-rare blood disorder. As prices continued to rise, industry analysts began to publish top 10 lists cataloging extremely expensive rare disease brands.

article thumbnail

New FDA Draft Guidance Signals Acceptance of Decentralized Trials (When Done Right)

MedCity News

he FDA has made a purposeful choice to write in broad strokes, stopping short of detailing ways to execute DCTs. Even so, the Agency is starting to acknowledge – and thereby support – the global shift towards expanded trial models. Essentially, the FDA is implicitly broadening the definition of clinical trials.

FDA 120
article thumbnail

Why is microbiological testing in medical device manufacturing important?

European Pharmaceutical Review

A paper published in the Journal of Pharmaceutical Research International has reviewed microbiological testing for medical devices and described their applications and challenges. Microbiological testing is essential for quality control , regulatory compliance and can help minimise the risk of microbial contamination. This approach can also help determine the appropriate manufacturing processes, sterilisation methods, and maintenance procedures.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Sanofi goes 'all in' on AI with new app to support company's manufacturing, R&D and more

Fierce Pharma

Sanofi is jumping on the artificial intelligence boat with a new app and a pledge to become “the first pharma company powered by artificial intelligence at scale.” | Sanofi's new app, plai, provides teams with a “360° view" to aid decision-making. The platform is one step in the company's digital transformation and goal to become the "first pharma powered by AI at scale.

article thumbnail

Working with Rare Disease Communities and Advocacy Groups

PM360

While all patient communities and advocacy groups offer patients, their families, and their caregivers support, advice, and information, rare disease patient groups can be especially tight-knit. With such limited information out there for some rare diseases, these groups are often the only resource for people looking for answers. Furthermore, these patients are typically the ones raising money for research into potential treatments and cures, as well as banding together to try to change governme

article thumbnail

To Get Better Staffing Levels, Hospitals Must Prioritize Nurses’ Hiring Demands

MedCity News

Many health systems aren’t employing the right tactics for hiring and retaining nurses, according to a new report. It argued that hospitals would have an easier time hiring and retaining nurses if they focused more on the things workers want most from their employers — such as flexible scheduling and professional development opportunities.

119
119
article thumbnail

Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial

Pharmaceutical Technology

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs). The developer has tested OVX836 in four completed clinical trials.

Safety 98
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Johnson & Johnson inks another Stelara patent settlement, this time with Alvotech and Teva

Fierce Pharma

Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. market without a patent infringement challenge by early 2025 thanks to a new settlement. | Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb. 21, 2025.

Marketing 324
article thumbnail

How can AI be best harnessed for pharmacovigilance data?

European Pharmaceutical Review

According to a recent review funded by GSK Biologicals, artificial intelligence (AI) and machine learning (ML) seems intuitively, to be well suited to perform pharmacovigilance (PV) tasks given the large volume of data, high degree of uncertainty and need to learn from data. However, the paper highlighted the challenges these technologies hold for analytics.

Safety 98
article thumbnail

Ipsen Itching Drug Scratches Off a Second FDA Approval in Rare Liver Indication

MedCity News

Ipsen drug Bylvay is now FDA approved for treating pruritus, or severe itching, which is a complication of the rare liver disease Alagille syndrome. The oral drug was previously approved for treating pruritus in another rare inherited liver disease called PFIC.

FDA 119
article thumbnail

Improving Rare Disease Clinical Trial Design

PM360

According to the National Organization for Rare Disorders (NORD) , there are over 7,000 known rare diseases, with 90% having no effective treatment method or cure. 1 When an individual is diagnosed with a rare disease, they often experience fear, uncertainty, and anxiety. Obtaining a diagnosis is only the first step, leaving many without the direction or resources to find the additional medical care they need.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time